The innovative “Diagnostic Tampon” already makes use of PCR testing technology to enable women and individuals who were assigned female at birth (AFAB) to screen their microbiome and test for STIs from the comfort and convenience of their own homes, including chlamydia, gonorrhoea, trichomonas, mycoplasma and ureaplasma.
With the launch of a screening kit for 14 high-risk HPV infections, the company is taking things a step further. Because the majority of HPV strains don’t cause any symptoms, early detection is essential. Eight in ten people will have HPV at some point in their lives, making HPV infections quite common. Many people are still unaware of how to treat HPV and avoid any potential problems.
According to the sources, tampons are preferred over swabs by both patients and professionals. Utilised in the same manner as a regular tampon, Daye’s exclusive HPV Diagnostic Tampon is more accurate than a swab and more pleasant than a speculum.
Persistent high-risk HPV infections are the cause of nearly all cases of cervical cancer (99.8%) and the virus can also affect fertility and contribute to mouth cancer. One of the deadliest illnesses for women is cervical cancer and the NHS hasn’t been able to reach its objective for cervical cancer screening since the COVID pandemic.
Daye will offer customised aftercare as part of the programme, which will include prescription medications and gynaecological health specialists’ visits. Additionally, the firm will support the advancement of HPV vaccination campaigns by offering HPV vaccines as a component of their aftercare services. A patient will be referred for a pap smear by Daye’s network of NHS specialists if their test results indicate that they have a high-risk HPV strain.
For more details : https://euroinsightscare.com
